doi: 10.1038/nbt0904-1087.
Goodbye Columbus! New NRDOs forego discovery
- PMID: 15340473
- DOI: 10.1038/nbt0904-1087
Item in Clipboard
Goodbye Columbus! New NRDOs forego discovery
Nat Biotechnol.
2004 Sep.
No abstract available
Similar articles
-
Redesigner drugs.Nat Biotechnol. 2004 Aug;22(8):953-7. doi: 10.1038/nbt0804-953. Nat Biotechnol. 2004. PMID: 15286643
-
The premium of a big pharma license deal.Nat Biotechnol. 2014 Jul;32(7):617-9. doi: 10.1038/nbt.2946. Nat Biotechnol. 2014. PMID: 25004224 No abstract available.
-
More than meets the eyes?Nat Biotechnol. 2004 Oct;22(10):1221. doi: 10.1038/nbt1004-1221. Nat Biotechnol. 2004. PMID: 15470455 No abstract available.
-
Research & market strategy: how choice of drug discovery approach can affect market position.Drug Discov Today. 2007 Apr;12(7-8):314-8. doi: 10.1016/j.drudis.2007.02.014. Epub 2007 Mar 7. Drug Discov Today. 2007. PMID: 17395091 Review.
-
R&D technology investments: misguided and expensive or a better way to discover medicines?Drug Discov Today. 2006 Sep;11(17-18):775-84. doi: 10.1016/j.drudis.2006.07.007. Drug Discov Today. 2006. PMID: 16935744 Review.
Cited by
-
Wasting cash--the decline of the British biotech sector.Nat Biotechnol. 2009 Jun;27(6):531-7. doi: 10.1038/nbt0609-531. Nat Biotechnol. 2009. PMID: 19513054
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
